Sentences with phrase «lymphoma patients after»

Beilhack and colleagues found that a slightly modified version of STAR2 has a similar effect on human T reg cells, suggesting that the approach could also prevent GvHD in leukemia and lymphoma patients after bone marrow or hematopoietic stem cell transplants.

Not exact matches

In clinical trials the treatment — which involves extracting individual patients» immune T - cells, modifying them to seek out tell - tale biological markers associated with blood cancers like aggressive lymphoma, and then pumping those modified killer cells back into the body — has shown major promise, in some cases eliminating all signs of the cancer in patients six months after treatment.

A team led by Øystein Fluge and Olav Mella at the Haukeland University Hospital in Bergen, Norway, discovered by chance that rituximab might help people with CFS after seeing symptoms ease in a patient who had both lymphoma and CFS (PLoS One, DOI: 10.1371 / journal.pone.0026358).

Experience with lymphoma patients, who receive a transplant of their own blood or bone cells after radiation to wipe out their cancer, has shown «there's no doubt it helps,» says bone marrow transplant expert Nelson Chao of Duke University in Durham, North Carolina.

Scientists in Germany have developed a new approach that may prevent leukemia and lymphoma patients from developing graft - versus - host disease (GvHD) after therapeutic bone marrow transplants.

Their team discovered by accident that rituximab might work against CFS after seeing symptoms ease in a patient who had both lymphoma and CFS.

The therapy is approved by the U.S. Food and Drug Administration for relapsed or treatment - resistant Hodgkin lymphoma, and it is commonly prescribed to patients whose disease has progressed after autologous stem cell transplant, a procedure that replenishes the bone marrow with the patient's own healthy stem cells after therapy.

The FDA granted accelerated approval to nivolumab (Opdivo), an anti-PD-1 checkpoint inhibitor, for patients with classical Hodgkin lymphoma (cHL) whose disease has relapsed or progressed after stem cell transplantation and the targeted antibody brentuximab vedotin (Adcetris).

The FDA granted approval to Yescarta ™ (axicabtagene ciloleucel, Kite / Gilead) for the treatment of adult patients with several types of non-Hogdkin large B cell lymphoma that is refractory or has relapsed after at least two previous systemic treatments.

Scope: 22 institutions Treatment: CD19 - targeting CAR T - cell therapy Results: 42 % of patients with aggressive large B - cell lymphoma remained in remission after 15 months

Brentuximab vedotin was previously approved by the FDA to treat cHL after relapse, cHL after stem cell transplant when a patient is at a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after failure of other treatment, and primary cutaneous ALCL after failure of other treatment.

As many as 30 percent of patients who survive childhood Hodgkin lymphoma develop a secondary cancer after diagnosis, primarily breast cancer, non-Hodgkin lymphoma, thyroid cancer or acute leukemia.

CAR T - cell Therapy: Scott McIntyre's Story After many treatments for his B - cell lymphoma failed, Scott McIntyre became the first UChicago Medicine patient to undergo CAR T - cell gene therapy in a clinical trial.

The US Food and Drug Administration (FDA) has granted Priority Review designation for tisagenlecleucel (Kymriah), formerly known as CTL019, for treatment of adult patients with relapsed or refractory diffuse large B - cell lymphoma (DLBCL) who are ineligible for, or have relapsed after, autologous stem cell transplant.

The US FDA has granted Priority Review designation for tisagenlecleucel (Kymriah) for treatment of adult patients with relapsed or refractory diffuse large B - cell lymphoma who are ineligible for, or have relapsed after, ASCT.

Ibrutinib is also approved to treat chronic lymphocytic leukemia / small lymphocytic lymphoma, including patients with 17p deletion, mantle cell lymphoma after at least one prior therapy, and patients with Waldenstrom macroglobulinemia.

Dr. Diefenbach initiated the trial after her research revealed that immune dysfunction in patients with Hodgkin lymphoma could indicate that some standard treatments were less likely to work.

Positron emission tomography (PET) imaging of metabolic tumor burden at diagnosis and after induction therapy can help identify patients most at risk of follicular lymphoma (FL) recurrence, but more work is needed to differentiate high - risk and moderate - risk patients, suggested findings from a pooled analysis of data from three prospective clinical trials, published in Blood.

Patients with Crohn's disease, psoriasis, rheumatoid arthritis, B cell lymphoma and chronic lymphocytic leukemia have also developed the devastating brain disease after immunosuppressant therapy with natalizumab and other drugs.

July 25, 2011 Two genetic variations predict second cancers after radiation treatment for children with Hodgkin lymphoma A genome - wide association study published in the August issue of Nature Medicine has found two tiny genetic variations that can predict which patients with Hodgkin's lymphoma are most likely to develop radiation - induced second cancers years after treatment.

Should all patients with Hodgkin lymphoma who relapse after autologous SCT be considered for allogeneic SCT?

Hodgkin lymphoma is typically considered to be more treatable, and more than 90 % of patient survive more than five years after their diagnosis.

Thirty - six percent of over 100 very ill lymphoma patients appeared disease - free six months after a single treatment, according to results released by the treatment's maker, Kite Pharma of Santa Monica, Calif..